[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.4062/biomolther.2012.20.3.256

Tamoxifen Resistance in Breast Cancer

Chang, Min-Sun (Department of Medical and Pharmaceutical Science, College of Science, Sookmyung Women's University)

Publication Information

Biomolecules & Therapeutics / v.20, no.3, 2012 , pp. 256-267 More about this Journal

Abstract

Tamoxifen is a central component of the treatment of estrogen receptor (ER)-positive breast cancer as a partial agonist of ER. It has been clinically used for the last 30 years and is currently available as a chemopreventive agent in women with high risk for breast cancer. The most challenging issue with tamoxifen use is the development of resistance in an initially responsive breast tumor. This review summarizes the roles of ER as the therapeutic target of tamoxifen in cancer treatment, clinical values and issues of tamoxifen use, and molecular mechanisms of tamoxifen resistance. Emerging knowledge on the molecular mechanisms of tamoxifen resistance will provide insight into the design of regimens to overcome tamoxifen resistance and discovery of novel therapeutic agents with a decreased chance of developing resistance as well as establishing more efficient treatment strategies.

Keywords

Breast cancer; Estrogen receptor; Tamoxifen; Antiestrogen resistance;

Citations & Related Records

Reference

1	Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., Livingston, R. B., Davidson, N. E., Norton, L., Perez, E. A., Abrams, J. S., Cameron, D. A., Palmer, M. J. and Pater, J. L.; National Cancer Institute of Canada Clinical Trials Group MA.17. (2007) Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J. Clin. Oncol. 25, 2006-2011. DOI
2	Dowsett, M. and Haynes, B. P. (2003) Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. J. Steroid Biochem. Mol. Biol. 86, 255-263. DOI
3	EBCTCG (Early Breast Cancer Trialist' Collaborative Group). (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351, 1451-1467. DOI
4	EBCTCG (Early Breast Cancer Trialist' Collaborative Group). (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717. DOI
5	Encarnación, C. A., Ciocca, D. R., McGuire, W. L., Clark, G. M., Fuqua, S. A. and Osborne, C. K. (1993) Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res. Treat. 26, 237-246. DOI
6	Fan, P. W. and Boltonm J, L. (2001) Bioactivation of tamoxifen to metabolite E quinone methide: reaction with glutathione and DNA. Drug Metab. Dispos. 29, 891-896.
7	Forbes, J. F., Cuzick, J., Buzdar, A., Howell, A., Tobias, J. S. and Baum, M; Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9, 45-53. DOI
8	Fridovich, I. (1999) Fundamental aspects of reactive oxygen species, or what's the matter with oxygen? Ann. N. Y. Acad. Sci. 893, 13-18. DOI
9	Fuqua, S. A. (1994) Estrogen receptor mutagenesis and hormone resistance. Cancer 74 (3 Suppl), 1026-1029. DOI
10	Clarke, R. B., Howell, A., Potten, C. S. and Anderson, E. (1997) Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res. 57, 4987-4991.
11	Crawford, A. C., Riggins, R. B., Shajahan, A. N., Zwart, A. and Clarke, R. (2010) Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis. PLoS One 5, e8604. DOI
12	Creighton, C. J., Massarweh, S., Huang, S., Tsimelzon, A., Hilsenbeck, S. G., Osborne, C. K., Shou, J., Malorni, L. and Schiff, R. (2008) Development of resistance to targeted therapies transforms the clinically associated molecular profi le subtype of breast tumor xenografts. Cancer Res. 68, 7493-7501. DOI
13	Crewe, H. K., Notley, L. M., Wunsch, R. M., Lennard, M. S. and Gillam, E. M. (2002) Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab. Dispos. 30, 869-874. DOI
14	Croker, A. K., Goodale, D., Chu, J., Postenka, C., Hedley, B. D., Hess, D. A. and Allan, A. L. (2009) High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J. Cell Mol. Med. 13, 2236-2252. DOI
15	Dawson, S. J., Provenzano, E. and Caldas, C. (2009) Triple negative breast cancers: clinical and prognostic implications. Eur. J. Cancer 45 Suppl 1, 27-40. DOI ScienceOn
16	Bursch, W., Ellinger, A., Kienzl, H., Török, L., Pandey, S., Sikorska, M., Walker, R. and Hermann, R. S. (1996) Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis 17, 1595-1607. DOI
17	Denton, K. M., Shweta, A. and Anderson, W. P. (2002) Preglomerular and postglomerular resistance responses to different levels of sympathetic activation by hypoxia. J. Am. Soc. Nephrol. 13, 27-34.
18	Dontu, G., El-Ashry, D. and Wicha, M. S. (2004) Breast cancer, stem/ progenitor cells and the estrogen receptor. Trends Endocrinol. Metab. 15, 193-197. DOI
19	Brzozowski, A. M., Pike, A. C., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Ohman, L., Greene, G. L., Gustafsson, J. A. and Carlquist, M. (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753-758. DOI ScienceOn
20	Caraci, F., Crupi, R., Drago, F. and Spina. E. (2011) Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr. Drug Metab. 12, 570-577. DOI
21	Cavalieri, E., Chakravarti, D., Guttenplan, J., Hart, E., Ingle, J., Jankowiak, R., Muti, P., Rogan, E., Russo, J., Santen, R. and Sutter, T. (2006) Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim. Biophys. Acta 1766, 63-78.
22	Chang, M., Liu, H. and Jordan, V. C. (2002). Hormonal and growth factors. In Cancer of the Breast (P. M. Dansette, R. Snyder, M. Delaforge, G. G. Gibson, H. Greim, D. J. Jollow, T. J. Monks and I. G. Sipes, Eds.), pp. 417-441. Saunders, Philadelphia, USA.
23	Chang, X. Z., Li, D. Q., Hou, Y. F., Wu, J., Lu, J.S., Di, G. H., Jin, W., Ou, Z. L., Shen, Z. Z. and Shao, Z. M. (2007) Identifi cation of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res. 9, R76. DOI
24	Yager, J. D. and Davidson, N. E. (2006) Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 354, 270-282. DOI
25	van den Berg, H. W., Lynch, M., Martin, J., Nelson, J., Dickson, G. R. and Crockard, A. D. (1989) Characterisation of a tamoxifenresistant variant of the ZR-75-1 human breast cancer cell line (ZR- 75-9a1) and ability of the resistant phenotype. Br. J. Cancer 59, 522-526. DOI
26	Webb, P., Nguyen, P., Shinsako, J., Anderson, C., Feng, W., Nguyen, M. P., Chen, D., Huang, S. M., Subramania,n S., McKinerney, E., Katzenellenbogen, B. S., Stallcup, M. R. and Kushner, P. J. (1998) Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol. Endocrinol. 12, 1605-1618. DOI
27	Wegman, P., Elingarami, S., Carstensen, J., Stål, O., Nordenskjöld, B. and Wingren, S. (2007) Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res. 9, R7. DOI
28	Yuan, J., Murrell, G. A., Trickett, A., Landtmeters, M., Knoops, B. and Wang, M. X. (2004) Overexpression of antioxidant enzyme peroxiredoxin 5 protects human tendon cells against apoptosis and loss of cellular function during oxidative stress. Biochim. Biophys. Acta 1693, 37-45. DOI
29	Clarke, R., Dickson, R. B. and Brünner, N. (1990) The process of malignant progression in human breast cancer. Ann. Oncol. 1, 401-407.
30	Clarke, R., Currier, S., Kaplan, O., Lovelace, E., Boulay, V., Gottesman, M. M. and Dickson, R. B. (1992) Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. J. Natl. Cancer Inst. 84, 1506-1512. DOI
31	Arpino, G., Gutierrez, C., Weiss, H., Rimawi, M., Massarweh, S., Bharwani, L., De Placido, S., Osborne, C. K. and Schiff, R. (2007) Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J. Natl. Cancer Inst. 99, 694-705. DOI
32	Banerjee, S., Saxena, N., Sengupta, K. and Banerjee, S. K. (2003) 17alpha-estradiol-induced VEGF-A expression in rat pituitary tumor cells is mediated through ER independent but PI3K-Akt dependent signaling pathway. Biochem. Biophys. Res. Commun. 300, 209-215. DOI
33	Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M. and Osborne, C. K. (1992) Estrogendependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat. 24, 85-95. DOI ScienceOn
34	Bjornström, L. and Sjöberg, M. (2005) Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol. 19, 833-842. DOI
35	Bocchinfuso, W. P. and Korach, K. S. (1997) Estrogen receptor residues required for stereospecifi c ligand recognition and activation. Mol. Endocrinol. 11, 587-594. DOI
36	Bolton, J. L. and Thatcher, G. R. (2008) Potential mechanisms of estrogen quinone carcinogenesis. Chem. Res. Toxicol. 21, 93-101. DOI
37	Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H. and Schiff, R. (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst. 96, 926-935. DOI
38	Yue, W., Wang, J. P., Li, Y., Bocchinfuso, W. P., Korach, K. S., Devanesan, P. D., Rogan, E., Cavalieri, E. and Santen, R. J. (2005) Tamoxifen versus aromatase inhibitors for breast cancer prevention. Clin. Cancer Res. 11, 925s-930s.
39	Zajchowski, D. A., Kauser, K., Zhu, D., Webster, L., Aberle, S., White, F. A. 3rd., Liu, H. L., Humm, R., MacRobbie, J., Ponte, P., Hegele- Hartung, C., Knauthe, R., Fritzemeier, K. H., Vergona, R. and Rubanyi, G. M. (2000) Identification of selective estrogen receptor modulators by their gene expression fingerprints. J. Biol. Chem. 275, 15885-15894. DOI
40	Zhou, Q., Atadja, P. and Davidson, N. E. (2007) Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biol. Ther. 6, 64-69. DOI
41	Stearns, V., Johnson, M. D., Rae, J. M., Morocho, A., Novielli, A., Bhargava, P., Hayes, D. F., Desta, Z. and Flockhart, D. A. (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 95, 1758-1764. DOI
42	Stingl, J. (2011) Estrogen and progesterone in normal mammary gland development and in cancer. Horm. Cancer 2, 85-90. DOI
43	Stoica, G. E., Franke, T. F., Moroni, M., Mueller, S., Morgan, E., Iann, M. C., Winder, A. D., Reiter, R., Wellstein, A., Martin, M. B. and Stoica, A. (2003) Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene 22, 7998-8011. DOI
44	Samaddar, J. S., Gaddy, V. T., Duplantier, J., Thandavan, S. P., Shah, M., Smith, M. J., Browning, D., Rawson, J., Smith, S. B., Barrett, J. T. and Schoenlein, P. V. (2008) A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Mol. Cancer Ther. 7, 2977-2987. DOI
45	Borges, S., Desta, Z., Li, L., Skaar, T. C., Ward, B. A., Nguyen, A., Jin, Y., Storniolo, A. M., Nikoloff, D. M., Wu, L., Hillman, G., Hayes, D. F., Stearns, V. and Flockhart, D. A. (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 80, 61-74. DOI
46	Brunner, N., Boysen, B., Jirus, S., Skaar, T. C., Holst-Hansen, C., Lippman, J., Frandsen, T., Spang-Thomsen, M., Fuqua, S. A. and Clarke, R. (1997) MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res. 57, 3486-3493.
47	Tan, T. T. and White, E. (2008) Therapeutic targeting of death pathways in cancer: mechanisms for activating cell death in cancer cells. Adv. Exp. Med. Biol. 615, 81-104. DOI
48	Tucker, A. N., Tkaczuk, K. A., Lewis, L. M., Tomic, D., Lim, C. K. and Flaws, J. A. (2005) Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 21, 61-72.
49	Tzukerman, M. T., Esty, A., Santiso-Mere, D., Danielian, P., Parker, M. G., Stein, R. B., Pike, J. W. and McDonnell, D. P. (1994) Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol. 8, 21-30. DOI
50	Schiff, R., Reddy, P., Ahotupa, M., Coronado-Heinsohn, E, Grim, M., Hilsenbeck, S. G., Lawrence, R., Deneke, S., Herrera, R., Chamness, G. C., Fuqua, S. A., Brown, P. H. and Osborne, C. K. (2000) Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J. Natl. Cancer Inst. 92, 1926-1934. DOI
51	Schroth, W., Antoniadou, L., Fritz, P., Schwab, M., Muerdter, T., Zanger, U. M., Simon, W., Eichelbaum, M. and Brauch, H. (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25, 5187-5193. DOI
52	Seo, M. J., Liu, X., Chang, M. and Park, J. H. (2012) GATA-binding protein 1 is a novel transcription regulator of peroxiredoxin 5 in human breast cancer cells. Int. J. Oncol. 40, 655-664.
53	Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A. and Greene, G. L. (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927-937. DOI ScienceOn
54	Anderson, W. F., Chatterjee, N., Ershler, W. B. and Brawley, O. W. (2002) Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res. Treat. 76, 27-36. DOI ScienceOn
55	Angel, P. and Karin, M. (1991) The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta 1072, 129-157.
56	Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M., Guan, X. Y., Sauter, G., Kallioniemi, O. P., Trent, J. M. and Meltzer, P. S. (1997) AIB1, a steroid receptor coactivator amplifi ed in breast and ovarian cancer. Science 277, 965-968. DOI
57	Sharma, D., Blum, J., Yang, X., Beaulieu, N., Macleod, A. R. and Davidson, N. E. (2005) Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol. Endocrinol. 19, 1740-1751. DOI
58	Sheridan, C., Kishimoto, H., Fuchs, R. K., Mehrotra, S., Bhat- Nakshatri, P., Turner, C. H., Goulet, R. Jr., Badve, S. and Nakshatri, H. (2006) CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 8, R59. DOI
59	Regan, M. M., Neven, P., Giobbie-Hurder, A., Goldhirsch, A., Ejlertsen, B., Mauriac, L., Forbes, J. F., Smith, I., Láng, I., Wardley, A., Rabaglio, M., Price, K. N., Gelber, R. D., Coates, A. S., Thürlimann, B.,; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG). (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol. 12, 1101-1108. DOI ScienceOn
60	Ricketts, D. and Coombes, R. C. (1989) What's new in steroid receptor immunocytochemistry in clinical oncology? Pathol. Res. Pract. 185, 935-941. DOI
61	Ring, A., Sestak, I., Baum, M., Howell, A., Buzdar, A., Dowsett, M., Forbes, J. F. and Cuzick, J. (2011) Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. J. Clin. Oncol. 29, 4266-4272. DOI
62	Russo, J. and Russo, I. H. (2006) The role of estrogen in the initiation of breast cancer. J. Steroid. Biochem. Mol. Biol. 102, 89-96. DOI
63	Paridaens, R. J., Dirix, L. Y., Beex, L. V., Nooij, M., Cameron, D. A., Cufer, T., Piccart, M. J., Bogaerts, J. and Therasse, P. (2008) Phase III study comparing exemestane with tamoxifen as fi rst-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J. Clin. Oncol. 26, 4883-4890. DOI
64	Russo, J., Ao, X., Grill, C. and Russo, I. H. (1999) Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res. Treat. 53, 217-227. DOI
65	Russo, J., Hu, Y. F., Yang, X. and Russo, I. H. (2000) Developmental, cellular, and molecular basis of human breast cancer. J. Natl. Cancer Inst. Monogr. 27, 17-37.
66	Russo, J., Reina, D., Frederick, J. and Russo, I. H. (1988) Expression of phenotypical changes by human breast epithelial cells treated with carcinogens in vitro. Cancer Res. 48, 2837-2857.
67	Pathak, D. N., Pongracz, K. and Bodell, W. J. (1996) Activation of 4-hydroxytamoxifen and the tamoxifen derivative metabolite E by uterine peroxidase to form DNA adducts: comparison with DNA adducts formed in the uterus of Sprague-Dawley rats treated with tamoxifen. Carcinogenesis 17, 1785-1790. DOI
68	Pavlik, E. J., Nelson, K., Srinivasan, S., Powell, D. E., Kenady, D. E., DePriest, P. D., Gallion, H. H. and van Nagell, J. R. Jr. (1992) Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity. Cancer Res. 52, 4106-4112.
69	Pike, M. C., Spicer, D. V., Dahmoush, L. and Press, M. F. (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev. 15, 17-35.
70	Qadir, M. A., Kwok, B., Dragowska, W. H., To, K. H., Le, D., Bally, M. B. and Gorski, S. M. (2008) Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization. Breast Cancer Res. Treat. 112, 389-403. DOI
71	Quick, E. L., Parry, E. M. and Parry, J. M. (2008) Do oestrogens induce chromosome specifi c aneuploidy in vitro, similar to the pattern of aneuploidy seen in breast cancer? Mutat. Res. 651, 46-55. DOI
72	Murdter, T. E., Schroth, W., Bacchus-Gerybadze, L., Winter, S., Heinkele, G., Simon, W., Fasching, P. A., Fehm, T.,; German Tamoxifen and AI Clinicians Group., Eichelbaum, M., Schwab, M. and Brauch, H. (2011) Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin. Pharmacol. Ther. 89, 708-717. DOI
73	Murphy, M. P. (2009) How mitochondria produce reactive oxygen species. Biochem. J. 417, 1-13. DOI
74	Myers, E., Hill, A. D., Kelly, G., McDermott, E. W., O'Higgins, N. J., Buggy, Y. and Young, L. S. (2005) ssociations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer. Clin. Cancer Res. 11, 2111-2122. DOI
75	Neumann, C. A. and Fang, Q. (2007) Are peroxiredoxins tumor suppressors? Curr. Opin. Pharmacol. 7, 375-380. DOI
76	O'Regan, R. M., Osipo, C., Ariazi, E., Lee, E. S., Meeke, K., Morris, C., Bertucci, A., Sarker, M. A., Grigg, R. and Jordan, V. C. (2006) Development and therapeutic options for the treatment of raloxifenestimulated breast cancer in athymic mice. Clin. Cancer Res. 12, 2255-2263. DOI
77	Mc Ilroy, M., Fleming, F. J., Buggy, Y., Hill, A. D. and Young, L. S. (2006) Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specifi c recurrence. Endocr. Relat. Cancer 13, 1135-1145. DOI
78	Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C., Hilsenbeck, S. G., Fuqua, S. A., Wong, J., Allred, D. C., Clark, G. M. and Schiff, R. (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl. Cancer Inst. 95, 353-361. DOI
79	Ouhtit, A., Abd Elmageed, Z. Y., Abdraboh, M. E., Lioe, T. F. and Raj, M. H. (2007) In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver. Am. J. Pathol. 171, 2033-2039. DOI
80	Massarweh, S. and Schiff, R. (2006) Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr. Relat. Cancer 13 Suppl 1, S15-24. DOI
81	McGuire, W. L., Horwitz, K. B., Pearson, O. H. and Segaloff, A. (1977) Current status of estrogen and progesterone receptors in breast cancer. Cancer 39 (6 Suppl), 2934-2947. DOI
82	Mikhaĭlov, V. M., Kropotov, A. V., Zelenin, A. V., Krutilina, R. I., Kolesnikov, V. A., Zelenina, I. A., Baranov, A. N., Shtein, G. I., Ostapenko, O. V., Tomilin, N. V. and Baranov, V. S. (2002) The BCL-xL and ACR-1 genes promote differentiation and reduce apoptosis in muscle fi bers of mdx mice. Genetika 38, 1445-1450.
83	Mosselman, S., Polman, J. and Dijkema, R. (1996) ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 392, 49-53. DOI
84	Mouridsen, H., Giobbie-Hurder, A., Goldhirsch, A., Thürlimann, B., Paridaens, R., Smith, I., Mauriac, L., Forbes, J. F., Price, K. N., Regan, M. M., Gelber, R. D. and Coates, A. S.; BIG 1-98 Collaborative Group. (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N. Engl. J. Med. 361, 766-776. DOI
85	Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T. M., Schiff, R., Del-Rio, A. L., Ricote, M., Ngo, S., Gemsch, J., Hilsenbeck, S. G., Osborne, C. K., Glass, C. K., Rosenfeld, M. G. and Rose, D. W. (1998) Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc. Natl. Acad. Sci. USA 95, 2920-2925. DOI
86	Munzone, E., Curigliano, G., Rocca, A., Bonizzi, G., Renne, G., Goldhirsch, A. and Nole, F. (2006) Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res. 8, R4. DOI
87	Kuiper, G. G., Carlsson, B., Grandien, K., Enmark, E., Haggblad, J., Nilsson, S. and Gustafsson, J. A. (1997) Comparison of the ligand binding specifi city and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138, 863-870. DOI
88	Kurosumi, M. (2003) Signifi cance of immunohistochemical assessment of steroid hormone receptor status for breast cancer patients. Breast Cancer 10, 97-104. DOI
89	Levenson, A. S., Catherino, W. H. and Jordan, V. C. (1997) Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J. Steroid. Biochem. Mol. Biol. 60, 261-268. DOI
90	Liehr, J. G. (1998) Catecholestrogens in the induction of tumors in the kidney of the Syrian hamster. Adv. Pharmacol. 42, 824-828.
91	List, H. J., Lauritsen, K. J., Reiter, R., Powers, C., Wellstein, A. and Riegel, A. T. (2001) Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogendependent growth of human MCF-7 breast cancer cells. J. Biol. Chem. 276, 23763-23768. DOI
92	Love, R. R. and Philips, J. (2002) Oophorectomy for breast cancer: history revisited. J. Natl. Cancer Inst. 94, 1433-1434. DOI
93	Karihtala, P., Mantyniemi, A., Kang, S. W., Kinnula, V. L. and Soini, Y. (2003) Peroxiredoxins in breast carcinoma. Clin. Cancer Res. 15, 3418-3424.
94	Lyko, F. and Brown, R. (2005) DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J. Natl. Cancer Inst. 97, 1498-1506. DOI
95	Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P. and Evans, R. M. (1995) The nuclear receptor superfamily: the second decade. Cell 83, 835-839. DOI ScienceOn
96	Jordan, V. C., Collins, M. M., Rowsby, L. and Prestwich, G. (1997) A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol. 75, 305-316.
97	Katzenellenbogen, B. S., Miller, M. A., Mullick, A. and Sheen, Y. Y. (1985) Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites. Breast Cancer Res. Treat. 5, 231-243. DOI
98	Keeling, J. W., Ozer, E., King, G. and Walker, F. (2000) Oestrogen receptor alpha in female fetal, infant, and child mammary tissue. J. Pathol. 191, 449-451. DOI
99	Kim, P. M. and Wells, P. G. (1996) Genoprotection by UDP-glucuronosyltransferases in peroxidase-dependent, reactive oxygen species-mediated micronucleus initiation by the carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene. Cancer Res. 56, 1526-1532.
100	Klinge, C. M. (2000) Estrogen receptor interaction with co-activators and co-repressors. Steroids 65, 227-251. DOI
101	Kryston, T. B., Georgiev, A. B., Pissis, P. and Georgakilas, A. G. (2011) Role of oxidative stress and DNA damage in human carcinogenesis. Mutat. Res. 711, 193-201. DOI ScienceOn
102	Johnson, M. D., Zuo, H., Lee, K. H., Trebley, J. P., Rae, J. M., Weatherman, R. V., Desta, Z., Flockhart, D. A. and Skaar, T. C. (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 85, 151-159. DOI
103	Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., Maurel, P., Relling, M., Brimer, C., Yasuda, K., Venkataramanan, R., Strom, S., Thummel, K., Boguski, M. S. and Schuetz, E. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391. DOI
104	Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K. H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., Blanchard, R., Nguyen, A., Ullmer, L., Hayden, J., Lemler, S., Weinshilboum, R. M., Rae, J. M., Hayes, D. F. and Flockhart, D. A. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. 97, 30-39. DOI
105	John, S., Nayvelt, I., Hsu, H. C., Yang, P., Liu, W., Das, G. M., Thomas, T. and Thomas, T. J. (2008) Regulation of estrogenic effects by beclin 1 in breast cancer cells. Cancer Res. 68, 7855-7863. DOI ScienceOn
106	Johnston, S. R. (2010) New strategies in estrogen receptor-positive breast cancer. Clin. Cancer Res. 16, 1979-1987. DOI
107	Johnston, S. R., Haynes, B. P., Smith, I. E., Jarman, M., Sacks, N. P., Ebbs, S. R. and Dowsett, M. (1993) Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet 342, 1521-1522. DOI
108	Johnston, S. R., Semiglazov, V. F., Manikhas, G. M., Spaeth, D., Romieu, G., Dodwell, D. J., Wardley, A. M., Neven, P., Bessems, A., Park, Y. C., De Porre, P. M., Perez Ruixo, J. J. and Howes, A. J. (2008) A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res. Treat. 110, 327-335. DOI
109	Jordan, V. C. (2004) Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 5, 207-213. DOI
110	Jordan, V. C. (1977) Effects of tamoxifen in relation to breast cancer. Br. Med. J. 1, 1534-1535.
111	Howell, A., Robertson, J. F., Quaresma Albano, J., Aschermannova, A., Mauriac, L., Kleeberg, U. R., Vergote, I., Erikstein, B., Webster, A. and Morris, C. (2002) Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol. 20, 3396-3403. DOI
112	Hurtubise, A. and Momparler, R. L. (2006) Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells. Cancer Chemother. Pharmacol. 58, 618-625. DOI
113	Ingle, J. N., Mailliard, J. A., Schaid, D. J., Krook, J. E., Gesme, D. H., Jr, Windschitl, H. E., Pfeifl e, D.M., Etzell, P. S., Gerstner, J. G. and Long, H. J., et al. (1991) A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Cancer 68, 34-39. DOI
114	Jaiyesimi, I. A., Buzdar, A. U., Decker, D. A. and Hortobagyi, G. N. (1995) Use of tamoxifen for breast cancer: twenty-eight years later. J. Clin. Oncol. 13, 513-529.
115	Jemal, A., Siegel, R., Xu, J. and Ward, E. (2010) Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300. DOI
116	Jiang, S. Y., Langan-Fahey, S. M., Stella, A. L., McCague, R. and Jordan, V. C. (1992) Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER. Mol. Endocrinol. 6, 2167-2174. DOI
117	Graham, M. L., 2nd, Smith, J. A., Jewett, P. B. and Horwitz, K. B. (1992) Heterogeneity of progesterone receptor content and remodeling by tamoxifen characterize subpopulations of cultured human breast cancer cells: analysis by quantitative dual parameter flow cytometry. Cancer Res. 52, 593-602.
118	Jin, S. (2006) Autophagy, mitochondrial quality control, and oncogenesis. Autophagy 2, 80-84. DOI
119	Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., Livingston, R. B., Davidson, N. E., Norton, L., Perez, E. A., Abrams, J. S., Cameron, D. A., Palmer M. J. and Pater, J. L. (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated fi ndings from NCIC CTG MA.17. J. Natl. Cancer Inst. 97, 1262-1271. DOI
120	Gottardis, M. M. and Jordan, V. C. (1988) Development of tamoxifenstimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 48, 5183-5187.
121	Greene, G. L., Gilna, P., Waterfi eld, M., Baker, A., Hort, Y. and Shine, J. (1986) Sequence and expression of human estrogen receptor complementary DNA. Science 231, 1150-1154. DOI
122	Habel, L. A. and Stanford, J. L. (1993) Hormone receptors and breast cancer. Epidemiol. Rev. 15, 209-219.
123	Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Ström, A., Treuter, E., Warner, M. and Gustafsson, J. A. (2007) Estrogen receptors: how do they signal and what are their targets. Physiol. Rev. 87, 905-931. DOI
124	Henderson, B. E. and Feigelson, H. S. (2000) Hormonal carcinogenesis. Carcinogenesis 21, 427-433. DOI ScienceOn
125	Goetz, M. P., Knox, S. K., Suman, V. J., Rae, J. M., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W.L., Weinshilboum, R. M., Fritcher, E. G., Nibbe, A. M., Desta, Z., Nguyen, A., Flockhart, D. A., Perez, E. A. and Ingle, J. N. (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101, 113-121. DOI
126	Holloway, J. N., Murthy, S. and El-Ashry, D. (2004) A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-alpha down-regulation in breast cancer cells: the role of nuclear factor-kappaB. Mol. Endocrinol. 18, 1396-1410. DOI
127	Gee, J. M., Harper, M. E., Hutcheson, I. R., Madden, T. A., Barrow, D., Knowlden, J. M., McClelland, R. A., Jordan, N., Wakeling, A. E. and Nicholson, R. I. (2003) The antiepidermal growth factor receptor agent gefi tinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144, 5105-5117. DOI
128	Girault, I., Bièche, I. and Lidereau, R. (2006) Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer. Maturitas 54, 342-351. DOI
129	Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., Desta, Z., Perez, E. A. and Ingle, J. N. (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23, 9312-9318. DOI
130	Gonzalez-Angulo, A. M., Morales-Vasquez, F. and Hortobagyi, G. N. (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv. Exp. Med. Biol. 608, 1-22. DOI

Reference

1	Sara Kangaspeska. (2016) BMC Cancer Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer / 16 (1)
	Brett Fleisher. (2017) Pharmacological Research Application of pharmacometrics and quantitative systems pharmacology to cancer therapy: The example of luminal a breast cancer / 124 , 20
6	Gamze Guney Eskiler. (2016) Cell Biology and Toxicology An in vitro model for the development of acquired tamoxifen resistance / 32 (6) , 563
	Elizabeth Bafaro. (2017) Signal Transduction and Targeted Therapy The emerging role of zinc transporters in cellular homeostasis and cancer / 2 , 17029
	Vahideh Alinejad. (2017) Biomedicine & Pharmacotherapy The role of IL17B-IL17RB signaling pathway in breast cancer / 88 , 795
7	Parnaz Merikhian. (2017) Expert Review of Anticancer Therapy MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer / 17 (7) , 607
2	Jamunarani Veeraraghavan. (2016) Breast Cancer Research and Treatment Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications / 158 (2) , 219
	Eylem Kulkoyluoglu. (2016) Steroids Nuclear and extranuclear-initiated estrogen receptor signaling crosstalk and endocrine resistance in breast cancer / 114 , 41
	Tanmoy Bhowmik. (2017) Chemico-Biological Interactions Down–regulation of cyclin–dependent kinase-4 and MAPK through estrogen receptor mediated cell cycle arrest in human breast cancer induced by gold nanoparticle tagged toxin protein NKCT1 / 268 , 119
6	Jiwon Ko. (2015) Bioscience, Biotechnology, and Biochemistry β-Thujaplicin modulates estrogen receptor signaling and inhibits proliferation of human breast cancer cells / 79 (6) , 1011
	Shaymaa M. M. Yahya. (2017) Indian Journal of Clinical Biochemistry The Effect of Newly Synthesized Heterosteroids on miRNA34a, 98, and 214 Expression Levels in MCF-7 Breast Cancer Cells /
	Yuan-Ke Liang. (2017) Cancer Letters MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial–mesenchymal transition, decreased ERα expression and AKT activation / 386 , 65
2	Jung Min Nam. (2013) European Journal of Pharmaceutical Sciences Dithiiranylmethyloxy azaxanthone shows potent anti-tumor activity via suppression of HER2 expression and HER2-mediated signals in HER2-overexpressing breast cancer cells / 50 (2) , 181
2	(2017) Chemical Biology & Drug Design Nonsteroidal estrogen receptor isoform-selective biphenyls / 91 (2) , 620
6	(2018) Medicinal Research Reviews Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer / 38 (6) , 2058
1	(2018) Journal of Cellular Physiology AhR ligand aminoflavone suppresses α6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells / 234 (1) , 108
12	(2017) International Journal of Molecular Sciences Protein Kinase Targets in Breast Cancer / 18 (12) , 2543
4	(2017) Pharmaceuticals Molecular Docking and 3D-Pharmacophore Modeling to Study the Interactions of Chalcone Derivatives with Estrogen Receptor Alpha / 10 (4) , 81
1	(2018) Biophysical Reviews Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer / 10 (1) , 69
1651-226X	(2018) Acta Oncologica Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study / (1651-226X) , 1
41	(2012) Oncotarget p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells / 6 (41) , 43853
21	(2018) Molecular Biology of the Cell Cell cycle–dependent force transmission in cancer cells / 29 (21) , 2528
6	(2018) Drug Development Research Nonhormonal selective estrogen receptor modulator 1-(2-[4-{(3R,4S)-7-Methoxy-2, 2-dimethyl-3-phenyl-chroman-4yl}phenoxy]ethyl)pyrrolidine hydrochloride (ormeloxifene hydrochloride) for the treatment of breast cancer / 79 (6) , 275
8	(2018) Acta Pharmacologica Sinica The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8 / 39 (8) , 1338
5	(2018) International Journal of Radiation Biology Therapeutic potential of melatonin for breast cancer radiation therapy patients / 94 (5) , 472
5	(2018) Biomarkers in Medicine BP1, a potential biomarker for breast cancer prognosis / 12 (5) , 535
1	(2018) Scientific Reports Enhanced ZnR/GPR39 Activity in Breast Cancer, an Alternative Trigger of Signaling Leading to Cell Growth / 8 (1)
1	(2018) Cancers Interplay between Epigenetics, Expression of Estrogen Receptor- α, HER2/ERBB2 and Sensitivity of Triple Negative Breast Cancer Cells to Hormonal Therapy / 11 (1) , 13
00099163	(2019) Clinical Genetics Liquid biopsy in breast cancer: A comprehensive review / (00099163)
1573-7217	(2019) Breast Cancer Research and Treatment SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma / (1573-7217)
6	(2015) Drug metabolism and disposition: the biological fate of chemicals Induction of UDP-Glucuronosyltransferase 2B15 Gene Expression by the Major Active Metabolites of Tamoxifen, 4-Hydroxytamoxifen and Endoxifen, in Breast Cancer Cells / 43 (6) , 889
10	(2012) Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine CIP2A expression predicts recurrences of tamoxifen-treated breast cancer / 39 (10) , 101042831772206
7	(2018) Journal of medicinal chemistry Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer / 61 (7) , 2837
6	(2018) Molecular pharmaceutics Energy Metabolism Drugs Block Triple Negative Breast Metastatic Cancer Cell Phenotype / 15 (6) , 2151
2	(2012) Journal of breast cancer Cell Division Cycle Associated 8 Is a Key Regulator of Tamoxifen Resistance in Breast Cancer / 22 (2) , 237
1	(2012) Nutrition and cancer Antiproliferative Effect of <I>Trifolium Pratens L.</I> Extract in Human Breast Cancer Cells / 71 (1) , 128
None	(2012) Frontiers in oncology Novel Diphenylamine Analogs Induce Mesenchymal to Epithelial Transition in Triple Negative Breast Cancer / 9 (None) , 672
4	(2019) PLoS ONE Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells / 14 (4) , e0215894
5	(2019) Expert review of proteomics Molecular insights into cancer drug resistance from a proteomics perspective / 16 (5) , 413
None	(2012) The journal of venomous animals and toxins including tropical diseases BthTX-I from Bothrops jararacussu induces apoptosis in human breast cancer cell lines and decreases cancer stem cell subpopulation / 25 (None) , e20190010
19	(2012) Organic & biomolecular chemistry 1,2,4-Oxadiazole-5-ones as analogues of tamoxifen: synthesis and biological evaluation / 17 (19) , 4892
2	(2012) Molecular pharmacology Pharmacological, Mechanistic, and Pharmacokinetic Assessment of Novel Melatonin-Tamoxifen Drug Conjugates as Breast Cancer Drugs / 96 (2) , 272
2	(2012) Molecular pharmacology Modulation of Burst Firing of Neurons in Nucleus Reticularis of the Thalamus by GluN2C-Containing NMDA Receptors / 96 (2) , 193
1	(2020) Clinical cancer drugs The Potential Role of Claudins in Regulation of Metastasis and Development of Drug Resistance in Breast Cancer / 7 (1) , 25
5	(2012) Proteomics. Clinical applications Moonlighting Proteins and Cardiopathy in the Spatial Response of MCF‐7 Breast Cancer Cells to Tamoxifen / 13 (5) , 1900029
3	(2012) Oncology Overcoming Tamoxifen Resistance by Regulation of Del-1 in Breast Cancer / 97 (3) , 180
1	(2019) Scientific reports Involvement of the P2X7 receptor in the migration and metastasis of tamoxifen-resistant breast cancer: effects on small extracellular vesicles production / 9 (1) , 11587
None	(2012) Frontiers in Endocrinology IGFBP-1 Expression Promotes Tamoxifen Resistance in Breast Cancer Cells via Erk Pathway Activation / 11 (None) , 233
3	(2012) Cells Therapeutic Potential of Autophagy Modulation in Cholangiocarcinoma / 9 (3) , 614
10	(2020) British journal of pharmacology : BJP Overcoming tamoxifen resistance in oestrogen receptor‐positive breast cancer using the novel thiosemicarbazone anti‐cancer agent, <SMALL>DPC</SMALL> / 177 (10) , 2365
4	(2020) Drug development research Synthesis of novel flexible tamoxifen analogues to overcome CYP2D6 polymorphism and their biological evaluation on MCF‐7 cell line / 81 (4) , 444
6	(2012) Cells The Network of Angiotensin Receptors in Breast Cancer / 9 (6) , 1336
3	(2012) South Asian journal of cancer Incidence of Hyperglycemia/Secondary Diabetes in Women who have Undergone Curative Chemotherapy for Breast Cancer: First Study from India / 9 (3) , 130
4	(2020) Journal of essential oil-bearing plants Chemical Composition of Essential Oil of <I>Garcinia gummi-gutta</I> and Its Antimicrobial and Cytotoxic Activities / 23 (4) , 832
10	(2012) Asian journal of organic chemistry Recent Advances in the Synthesis of Tamoxifen and Analogues in Medicinal Chemistry / 9 (10) , 1432
19	(2012) Genes & development Point-activated ESR1<SUP>Y541S</SUP> has a dramatic effect on the development of sexually dimorphic organs / 34 (19) , 1304
8	(2012) The British journal of cancer Progesterone receptor membrane component 1 promotes the growth of breast cancers by altering the phosphoproteome and augmenting EGFR/PI3K/AKT signalling / 123 (8) , 1326
None	(2012) European journal of medicinal chemistry Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment / 208 (None) , 112831
1	(2020) Scientific reports Tamoxifen induces hypercoagulation and alterations in ERα and ERβ dependent on breast cancer sub-phenotype ex vivo / 10 (1) , 19256
12	(2012) Molecular therapy : the journal of the American Society of Gene Therapy Adenylate Kinase 4 Modulates the Resistance of Breast Cancer Cells to Tamoxifen through an m6A-Based Epitranscriptomic Mechanism / 28 (12) , 2593
24	(2020) Journal of medicinal chemistry Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer / 63 (24) , 15094
p6	(2012) Materials today: proceedings Synthesis, characterization and molecular docking of new gold complexes as a breast anticancer / 45 (p6) , 5635
None	(2012) Integrative cancer therapies Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine / 20 (None) , 153473542199682
None	(2012) BioMed research international In Silico Screening of Marine Compounds as an Emerging and Promising Approach against Estrogen Receptor Alpha-Positive Breast Cancer / 2021 (None) , 1
None	(2021) European journal of pharmacology Pharmacologic downregulation of protein arginine methyltransferase1 expression by adenosine dialdehyde increases cell senescence in breast cancer / 891 (None) , 173697
None	(2012) Frontiers in Endocrinology Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer / 12 (None) , 599586
1	(2012) Clinical obesity Impact of sex hormones dysregulation and adiposity on the outcome of postmenopausal breast cancer patients / 11 (1) , None
2	(2012) Pharmaceuticals Synthesis and Biological Evaluation of 1-(Diarylmethyl)-1H-1,2,4-triazoles and 1-(Diarylmethyl)-1H-imidazoles as a Novel Class of Anti-Mitotic Agent for Activity in Breast Cancer / 14 (2) , 169
4	(2021) Molecules Novel Biphenyl Amines Inhibit Oestrogen Receptor (ER)-α in ER-Positive Mammary Carcinoma Cells / 26 (4) , 783
8	(2012) Cancers Plasmin and Plasminogen System in the Tumor Microenvironment: Implications for Cancer Diagnosis, Prognosis, and Therapy / 13 (8) , 1838
2	(2012) Journal of mammary gland biology and neoplasia Breast Cancer Response to Therapy: Can microRNAs Lead the Way? / 26 (2) , 157
6	(2012) Molecular cancer research Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models / 19 (6) , 1026
11	(2012) Cancers TNFα Enhances Tamoxifen Sensitivity through Dissociation of ERα-p53-NCOR1 Complexes in ERα-Positive Breast Cancer / 13 (11) , 2601
11	(2012) Cancers Pharmacological Inhibition of CBP/p300 Blocks Estrogen Receptor Alpha (ERα) Function through Suppressing Enhancer H3K27 Acetylation in Luminal Breast Cancer / 13 (11) , 2799
12	(2012) Cancers CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers / 13 (12) , 2872
6	(2012) ACS biomaterials science & engineering Collagen I Fibrous Substrates Modulate the Proliferation and Secretome of Estrogen Receptor-Positive Breast Tumor Cells in a Hormone-Restricted Microenvironment / 7 (6) , 2430
7	(2012) Chemical research in toxicology ATF3 Modulates the Resistance of Breast Cancer Cells to Tamoxifen through an <I>N</I><SUP>6</SUP>-Methyladenosine-Based Epitranscriptomic Mechanism / 34 (7) , 1814
16	(2012) Journal of medicinal chemistry GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer / 64 (16) , 11841
4	(2012) Breast disease.: An International Journal The effect of IL-1β on MRP2 expression and tamoxifen toxicity in MCF-7 breast cancer cells / 40 (4) , 263
42	(2021) ACS omega Targeting Estrogen Receptor-Positive Breast Microtumors with Endoxifen-Conjugated, Hypoxia-Sensitive Polymersomes / 6 (42) , 27654
None	(2012) Cytokine & growth factor reviews Role of TGF-β signaling in the mechanisms of tamoxifen resistance / 62 (None) , 62
None	(2022) Annals of medicine and surgery microRNA-221 and tamoxifen resistance in luminal-subtype breast cancer patients: A case-control study / 73 (None) , 103092